COVID-19
Conditions
Keywords
Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), coronavirus
Brief summary
The primary objectives of the study are: * To characterize the concentrations of casirivimab+imdevimab in serum over time * To evaluate the safety and tolerability of casirivimab+imdevimab The secondary objective of the study is: • To assess the immunogenicity of casirivimab+imdevimab
Interventions
Single dose weight-based equivalent administered intravenously (IV)
Sponsors
Regeneron Pharmaceuticals
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Minutes to 17 Years
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: 1. Has SARS-CoV-2 positive antigen or molecular diagnostic test ≤72 hours prior to study enrollment Note: historical record of positive result is acceptable as long as the sample was collected ≤72 hours prior to enrollment 2. Has symptoms consistent with COVID-19, as determined by the investigator, with onset ≤ 14 days before dosing 3. Hospitalized due to COVID-19 4. Provide informed consent signed by study patient or legally acceptable representative/guardian Key
Exclusion criteria
1. In the opinion of the investigator, unlikely to survive for \>96 hours from screening 2. Neonates having gestational age of \<29 weeks and weight \<1.1 kg 3. Receiving extracorporeal membrane oxygenation (ECMO) 4. Has new-onset stroke or seizure disorder during hospitalization 5. Initiated on renal replacement therapy due to COVID-19 6. Has circulatory shock requiring vasopressors on dosing day Note: Patients who require vasopressors for sedation-related hypotension or reasons other than circulatory shock may be eligible in this study 7. Participation in a clinical research study, including any double-blind study, evaluating an investigational product within 30 days and less than 5 half-lives of the investigational product prior to the screening visit 8. Members of the clinical site study team and/or their immediate family 9. Plans to receive an investigational or approved SARS-CoV-2 vaccine within 90 days after study drug administration based on current Centers for Disease Control vaccination guidelines (CDC, 2021). Refer to the latest CDC guidance for any updates. Note: Patients who have already completed vaccination prior to study enrollment may be allowed in the study. 10. Prior use (within 90 days prior to study drug administration) or current use of any investigational, authorized, or approved passive antibody for prophylaxis of SARS-CoV-2 infection, including convalescent plasma, convalescent sera, hyperimmune globulin, or other monoclonal antibodies (eg, bamlanivimab and etesevimab, sotrovimab) Note: Other protocol defined Inclusion/
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Concentrations of casirivimab+imdevimab in serum over time | Through day 169 |
| Proportion of patients with treatment-emergent serious adverse events (SAEs) | Through day 29 |
| Proportion of patients with infusion-related reactions | Through day 4 |
| Proportion of patients with hypersensitivity reactions | Through day 29 |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of anti-drug antibodies (ADA) to casirivimab+imdevimab over time | Through day 169 |
| Incidence of neutralizing antibodies (NAb) to casirivimab+imdevimab over time | Through day 169 |
Countries
United States
Outcome results
None listed